Logo image of BHVN

BIOHAVEN LTD (BHVN) Stock Fundamental Analysis

NYSE:BHVN - New York Stock Exchange, Inc. - VGG1110E1079 - Common Stock - Currency: USD

29.86  -0.54 (-1.78%)

After market: 29.99 +0.13 (+0.44%)

Fundamental Rating

2

Taking everything into account, BHVN scores 2 out of 10 in our fundamental rating. BHVN was compared to 572 industry peers in the Biotechnology industry. The financial health of BHVN is average, but there are quite some concerns on its profitability. BHVN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BHVN has reported negative net income.
BHVN had a negative operating cash flow in the past year.
In the past 5 years BHVN always reported negative net income.
In the past 5 years BHVN always reported negative operating cash flow.
BHVN Yearly Net Income VS EBIT VS OCF VS FCFBHVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M -400M -500M

1.2 Ratios

Looking at the Return On Assets, with a value of -157.55%, BHVN is doing worse than 84.99% of the companies in the same industry.
BHVN has a Return On Equity of -254.53%. This is in the lower half of the industry: BHVN underperforms 71.20% of its industry peers.
Industry RankSector Rank
ROA -157.55%
ROE -254.53%
ROIC N/A
ROA(3y)-105.39%
ROA(5y)-115.24%
ROE(3y)-272.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BHVN Yearly ROA, ROE, ROICBHVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2K 4K 6K

1.3 Margins

BHVN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BHVN Yearly Profit, Operating, Gross MarginsBHVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, BHVN has more shares outstanding
Compared to 5 years ago, BHVN has more shares outstanding
BHVN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BHVN Yearly Shares OutstandingBHVN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
BHVN Yearly Total Debt VS Total AssetsBHVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

BHVN has an Altman-Z score of 1.41. This is a bad value and indicates that BHVN is not financially healthy and even has some risk of bankruptcy.
BHVN's Altman-Z score of 1.41 is fine compared to the rest of the industry. BHVN outperforms 70.16% of its industry peers.
There is no outstanding debt for BHVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.41
ROIC/WACCN/A
WACCN/A
BHVN Yearly LT Debt VS Equity VS FCFBHVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 2.89 indicates that BHVN has no problem at all paying its short term obligations.
BHVN has a worse Current ratio (2.89) than 65.97% of its industry peers.
A Quick Ratio of 2.89 indicates that BHVN has no problem at all paying its short term obligations.
BHVN's Quick ratio of 2.89 is on the low side compared to the rest of the industry. BHVN is outperformed by 64.22% of its industry peers.
Industry RankSector Rank
Current Ratio 2.89
Quick Ratio 2.89
BHVN Yearly Current Assets VS Current LiabilitesBHVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for BHVN have decreased strongly by -30.40% in the last year.
EPS 1Y (TTM)-30.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BHVN will show a small growth in Earnings Per Share. The EPS will grow by 5.15% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-61.61%
EPS Next 2Y-7.48%
EPS Next 3Y1.08%
EPS Next 5Y5.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BHVN Yearly Revenue VS EstimatesBHVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B
BHVN Yearly EPS VS EstimatesBHVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BHVN. In the last year negative earnings were reported.
Also next year BHVN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BHVN Price Earnings VS Forward Price EarningsBHVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BHVN Per share dataBHVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.48%
EPS Next 3Y1.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BHVN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOHAVEN LTD

NYSE:BHVN (3/7/2025, 8:07:30 PM)

After market: 29.99 +0.13 (+0.44%)

29.86

-0.54 (-1.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-20 2025-03-20/amc
Inst Owners89.56%
Inst Owner Change6%
Ins Owners11.24%
Ins Owner Change0.21%
Market Cap3.05B
Analysts87.27
Price Target66.06 (121.23%)
Short Float %10.1%
Short Ratio8.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-50.03%
Min EPS beat(2)-101.89%
Max EPS beat(2)1.84%
EPS beat(4)1
Avg EPS beat(4)-40.86%
Min EPS beat(4)-101.89%
Max EPS beat(4)1.84%
EPS beat(8)2
Avg EPS beat(8)-39.78%
EPS beat(12)3
Avg EPS beat(12)-38.87%
EPS beat(16)3
Avg EPS beat(16)-34.76%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.6%
PT rev (3m)0.96%
EPS NQ rev (1m)1.62%
EPS NQ rev (3m)1.84%
EPS NY rev (1m)-0.23%
EPS NY rev (3m)-1.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-6.67%
Revenue NY rev (3m)-6.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.64
P/tB 10.29
EV/EBITDA N/A
EPS(TTM)-9.35
EYN/A
EPS(NY)-6.54
Fwd EYN/A
FCF(TTM)-5.2
FCFYN/A
OCF(TTM)-5.16
OCFYN/A
SpS0
BVpS3.1
TBVpS2.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -157.55%
ROE -254.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-105.39%
ROA(5y)-115.24%
ROE(3y)-272.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 61.32%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.89
Quick Ratio 2.89
Altman-Z 1.41
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)182.81%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.33%
EPS Next Y-61.61%
EPS Next 2Y-7.48%
EPS Next 3Y1.08%
EPS Next 5Y5.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-71.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-103.71%
EBIT Next 3Y-11.54%
EBIT Next 5YN/A
FCF growth 1Y-26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.69%
OCF growth 3YN/A
OCF growth 5YN/A